Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cell therapy aims to tame lupus and muscle inflammation

NCT ID NCT07331272

First seen Jan 10, 2026 · Last updated Apr 30, 2026 · Updated 17 times

Summary

This early-stage study tests a new treatment called LUCAR-G79D in 38 adults with lupus or inflammatory myopathies that have not responded to standard therapies. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researchers will also track changes in disease activity over a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Nanfang Hospital

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Affiliated Hospital of Xuzhou Medical University

    RECRUITING

    Xuzhou, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Nanchang University

    NOT_YET_RECRUITING

    Nanchang, Jiangxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Third The People's Hospital of Bengbu

    RECRUITING

    Bengbu, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xiangya Hospital of Central South University

    NOT_YET_RECRUITING

    Changsha, Hunan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.